Mark Sullivan
CIK 1331843 · Chief Legal Officer · last filed 2026-03-26
Mark Sullivan is a Chief Legal Officer who has filed 23 SEC Form 4 insider transactions across 4 companies since 2011. The most recent filing shows the insider sold $197.7K of DFTX on Mar 26, 2026. Across all open-market trades the lifetime net is −$963.3K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $6.7M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$6.71M
4
23
-$963.3K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DFTX | Chief Legal Officer | 271,079 | $24.75 | $6.71M | -$197.7K | 2 | 2026-03-26 |
| Definium Therapeutics, Inc. (MNMD) Delisted | Chief Legal Officer | 282,576 | $15.00 | $4.24M | -$569.9K | 10 | 2025-12-29 |
| Carisma Therapeutics Inc. (SESN) Delisted | General Counsel & Secretary | 383,716 | $12.58 | $4.83M | -$152.1K | 6 | 2023-03-06 |
| MModal Inc. (MEDH) Delisted | Gen Counsel, CCO & Secretary | 39,268 | — | — | -$43.7K | 5 | 2012-01-04 |
Recent Filings
23 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-03-26 | DFTX | Sell (S) | −10,702 | -$197.7K | EDGAR |
| 2026-02-05 | DFTX | Grant (A) | +125,000 | $0 | EDGAR |
| 2025-12-29 | Definium Therapeutics, Inc. (MNMD) Delisted | Sell (S) | −11,276 | -$148.2K | EDGAR |
| 2025-09-26 | Definium Therapeutics, Inc. (MNMD) Delisted | Sell (S) | −11,278 | -$110.2K | EDGAR |
| 2025-06-26 | Definium Therapeutics, Inc. (MNMD) Delisted | Sell (S) | −11,491 | -$78.1K | EDGAR |
| 2025-03-26 | Definium Therapeutics, Inc. (MNMD) Delisted | Sell (S) | −6,576 | -$44.3K | EDGAR |
| 2025-03-13 | Definium Therapeutics, Inc. (MNMD) Delisted | Grant (A) | +150,000 | $0 | EDGAR |
| 2024-12-27 | Definium Therapeutics, Inc. (MNMD) Delisted | Sell (S) | −4,519 | -$33.6K | EDGAR |
| 2024-09-25 | Definium Therapeutics, Inc. (MNMD) Delisted | Sell (S) | −4,430 | -$26.5K | EDGAR |
| 2024-06-25 | Definium Therapeutics, Inc. (MNMD) Delisted | Sell (S) | −17,854 | -$128.9K | EDGAR |